<DOC>
	<DOC>NCT01461538</DOC>
	<brief_summary>This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies.</brief_summary>
	<brief_title>Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Anemia, Refractory</mesh_term>
	<mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Histologicallyconfirmed by central review CD30positive nonlymphomatous malignancy Have failed, refused, or have been deemed ineligible for standard therapy Measurable disease Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 or a Karnofsky or Lansky Performance Status score greater than or equal to 70 Primary diagnosis of lymphoma or central nervous system (CNS) malignancy History of another primary invasive malignancy that has not been definitively treated or in remission for at least 3 years Evidence of active cerebral/meningeal disease</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Acute Lymphoid Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Anemia, Refractory, with Excess of Blasts</keyword>
	<keyword>Antibodies, Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens, CD30</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Monomethyl Auristatin E</keyword>
</DOC>